Skip to content
Research Article Open access CC BY 4.0

Oral Biopharmaceutics and In vitro Pharmacokinetics of Commercially Available Pharmaceutical Formulations of Paracetamol: Implications in Paediatric Medicine

Goodnews Onyedikachi Ikeh, Nwafor MN, Ndubuisi MN, Okolo KO

Journal of Complementary and Alternative Medical Research · pp. 146–164 · Published 20 Dec 2024

10.9734/jocamr/2024/v25i12603

Abstract

Aim: This study aimed to compare the oral pharmacokinetics of different paediatric paracetamol dosage forms that are commercially available in Nigeria. Study Design: Experimental. Place and Duration of Study: Faculty of Pharmaceutical Sciences, Enugu State University of Science and Technology, between March and December 2023 Methodology: The study used the regular in vitro dialysis membrane method to predict the in vivo drug release of commercially available paracetamol syrups (n=5) and dispersible tablets (n=5) in the Nigerian market. The sink condition followed the Conventional USP dissolution method, using a dialysis membrane sac. The drug samples were studied in simulated salivary fluid of pH 7.4, simulated gastric fluid of pH 1.2, and simulated intestinal fluid of pH 6.5 over 8 hours to simulate their passage in the gastrointestinal tract. At predetermined time intervals, 5 ml of the dissolution medium was drawn out from the system, diluted appropriately and its absorbance measured against a suitable blank at λ = 250 nm using a UV/Vis Spectrophotometer, while a fresh volume of 5 ml of dissolution medium was introduced into the dissolution vessel after each withdrawal. Results: Syrup dosage forms showed a faster drug release kinetics, based on their values. Kinetic parameters obtained from the linear regression analysis of the in vitro release resulted in a zero-order release kinetics, with  for paracetamol paediatric syrups, and  for tablets. Two-way ANOVA test of the AUC of dosage forms showed that the time required to elicit therapeutic response was extremely significant (F=44.37, DFn=3, DFd= 32 and P-value < 0.0001). Conclusion: The comparative in vitro pharmacokinetic study of paracetamol dosage forms revealed that the paediatric syrup formula has a better release kinetics than the scaled down adult formula.

Paracetamol dosage forms paediatric medicine biopharmaceutics in vitro pharmacokinetics

References (33)

  1. 1 Coping with Chronic Illness in Childhood and Adolescence [DOI]
  2. 2 Paediatric pharmacokinetics: key considerations [DOI]
  3. 3 Paracetamol (acetaminophen) poisoning [DOI]
  4. 4 Understanding dosing: children are small adults, neonates are immature children [DOI]
  5. 5 Paediatric oral biopharmaceutics: Key considerations and current challenges [DOI]
  6. 6 Drug Formulations: Standards and Novel Strategies for Drug Administration in Pediatrics [DOI]
  7. 7 Assessment of Pharmacologic Area Under the Curve When Baselines are Variable [DOI]
  8. 8 Summary of the National Institute of Child Health and Human Development–Best Pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop–Pediatric Biopharmaceutics Classification System Working Group [DOI]
  9. 9 Orally Dispersible Dosage Forms for Paediatric Use: Current Knowledge and Development of Nanostructure-Based Formulations [DOI]
  10. 10 Microenvironmental pH Modification in Buccal/Sublingual Dosage Forms for Systemic Drug Delivery [DOI]
  11. 11 Orally disintegrating drug carriers for paediatric pharmacotherapy [DOI]
  12. 12 Paracetamol (acetaminophen) pharmacodynamics: interpreting the plasma concentration [DOI]
  13. 13 State of the art of paracetamol in acute pain therapy [DOI]
  14. 14 Paracetamol and metabolite pharmacokinetics in infants [DOI]
  15. 15 Review of paediatric gastrointestinal physiology data relevant to oral drug delivery [DOI]
  16. 16 Ontogeny of oral drug absorption processes in children [DOI]
  17. 17 Specific aspects of gastro-intestinal transit in children for drug delivery design [DOI]
  18. 18 Pharmacokinetic–Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance [DOI]
  19. 19 Model‐based clinical drug development in the past, present and future: a commentary [DOI]
  20. 20 Discharge Instruction Comprehension and Adherence Errors: Interrelationship Between Plan Complexity and Parent Health Literacy [DOI]
  21. 21 Assessing the In Vitro Drug Release from Lipid-Core Nanocapsules: a New Strategy Combining Dialysis Sac and a Continuous-Flow System [DOI]
  22. 22 Paracetamol (acetaminophen) use in infants and children was never shown to be safe for neurodevelopment: a systematic review with citation tracking [DOI]
  23. 23 Predicting In Vivo Efficacy from In Vitro Data: Quantitative Systems Pharmacology Modeling for an Epigenetic Modifier Drug in Cancer [DOI]
  24. 24 Administration of medicines to children: a practical guide [DOI]
  25. 25 Paracetamol use (and/or misuse) in children in Enugu, South-East, Nigeria [DOI]
  26. 26 Modelo de correlación farmacocinético In vitro-in vivo para el aseguramiento de la calidad de medicamentos antirretrovirales [DOI]
  27. 27 Pediatric pharmacokinetic considerations and implications for drug dosing [DOI]
  28. 28 Pattern and predictors of medication use among adults in southwestern Nigeria: A community‐based cross‐sectional study [DOI]
  29. 29 Perceptions and attitudes of pediatricians and families with regard to pediatric medication errors at home [DOI]
  30. 30 Suspected paracetamol overdose in Monrovia, Liberia: a matched case–control study [DOI]
  31. 31 Overview of Clinical Pharmacokinetics in Pediatrics: Possible Implications in Therapy [DOI]
  32. 32 Comparative quality assessment and in vitro dissolution profile of some paracetamol tablet generics marketed in Nigeria [DOI]
  33. 33 [Acetaminophen poisoning].

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

61

Page views

0

PDF downloads

16

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.